677 related articles for article (PubMed ID: 24373902)
1. Pharmacological characterization of the novel γ-secretase modulator AS2715348, a potential therapy for Alzheimer's disease, in rodents and nonhuman primates.
Mitani Y; Akashiba H; Saita K; Yarimizu J; Uchino H; Okabe M; Asai M; Yamasaki S; Nozawa T; Ishikawa N; Shitaka Y; Ni K; Matsuoka N
Neuropharmacology; 2014 Apr; 79():412-9. PubMed ID: 24373902
[TBL] [Abstract][Full Text] [Related]
2. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.
Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS
J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883
[TBL] [Abstract][Full Text] [Related]
3. BIIB042, a novel γ-secretase modulator, reduces amyloidogenic Aβ isoforms in primates and rodents and plaque pathology in a mouse model of Alzheimer's disease.
Scannevin RH; Chollate S; Brennan MS; Snodgrass-Belt PA; Peng H; Xu L; Jung MY; Bussiere T; Arastu MF; Talreja T; Xin Z; Dunstan RW; Fahrer D; Rohde E; Dunah AW; Wang J; Kumaravel G; Taveras AG; Moore Arnold H; Rhodes KJ
Neuropharmacology; 2016 Apr; 103():57-68. PubMed ID: 26690893
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological and Toxicological Properties of the Potent Oral
Wagner SL; Rynearson KD; Duddy SK; Zhang C; Nguyen PD; Becker A; Vo U; Masliah D; Monte L; Klee JB; Echmalian CM; Xia W; Quinti L; Johnson G; Lin JH; Kim DY; Mobley WC; Rissman RA; Tanzi RE
J Pharmacol Exp Ther; 2017 Jul; 362(1):31-44. PubMed ID: 28416568
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological properties of a novel and potent γ-secretase modulator as a therapeutic option for the treatment of Alzheimer's disease.
Murakami K; Watanabe T; Koike T; Kamata M; Igari T; Kondo S
Brain Res; 2016 Feb; 1633():73-86. PubMed ID: 26707977
[TBL] [Abstract][Full Text] [Related]
6. 1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity.
Imbimbo BP; Del Giudice E; Colavito D; D'Arrigo A; Dalle Carbonare M; Villetti G; Facchinetti F; Volta R; Pietrini V; Baroc MF; Serneels L; De Strooper B; Leon A
J Pharmacol Exp Ther; 2007 Dec; 323(3):822-30. PubMed ID: 17895400
[TBL] [Abstract][Full Text] [Related]
7. Amelioration of cognitive deficits in plaque-bearing Alzheimer's disease model mice through selective reduction of nascent soluble Aβ42 without affecting other Aβ pools.
Mitani Y; Yarimizu J; Akashiba H; Shitaka Y; Ni K; Matsuoka N
J Neurochem; 2013 May; 125(3):465-72. PubMed ID: 23240999
[TBL] [Abstract][Full Text] [Related]
8. Alzheimer's disease mutations in APP but not γ-secretase modulators affect epsilon-cleavage-dependent AICD production.
Dimitrov M; Alattia JR; Lemmin T; Lehal R; Fligier A; Houacine J; Hussain I; Radtke F; Dal Peraro M; Beher D; Fraering PC
Nat Commun; 2013; 4():2246. PubMed ID: 23907250
[TBL] [Abstract][Full Text] [Related]
9. TASTPM mice expressing amyloid precursor protein and presenilin-1 mutant transgenes are sensitive to γ-secretase modulation and amyloid-β₄₂ lowering by GSM-10h.
Hussain I; Harrison DC; Hawkins J; Chapman T; Marshall I; Facci L; Ahmed S; Brackenborough K; Skaper SD; Mead TL; Smith BB; Giblin GM; Hall A; Gonzalez MI; Richardson JC
Neurodegener Dis; 2011; 8(1-2):15-24. PubMed ID: 20689247
[TBL] [Abstract][Full Text] [Related]
10. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
[TBL] [Abstract][Full Text] [Related]
11. Characterization of FRM-36143 as a new γ-secretase modulator for the potential treatment of familial Alzheimer's disease.
Blain JF; Bursavich MG; Freeman EA; Hrdlicka LA; Hodgdon HE; Chen T; Costa DE; Harrison BA; Kapadnis S; Murphy DA; Nolan S; Tu Z; Tang C; Burnett DA; Patzke H; Koenig G
Alzheimers Res Ther; 2016 Aug; 8(1):34. PubMed ID: 27572246
[TBL] [Abstract][Full Text] [Related]
12. Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets.
Evin G; Zhu A; Holsinger RM; Masters CL; Li QX
J Neurosci Res; 2003 Nov; 74(3):386-92. PubMed ID: 14598315
[TBL] [Abstract][Full Text] [Related]
13. Autosomal-dominant Alzheimer's disease mutations at the same codon of amyloid precursor protein differentially alter Aβ production.
Suárez-Calvet M; Belbin O; Pera M; Badiola N; Magrané J; Guardia-Laguarta C; Muñoz L; Colom-Cadena M; Clarimón J; Lleó A
J Neurochem; 2014 Jan; 128(2):330-9. PubMed ID: 24117942
[TBL] [Abstract][Full Text] [Related]
14. Familial Alzheimer's disease mutations inhibit gamma-secretase-mediated liberation of beta-amyloid precursor protein carboxy-terminal fragment.
Wiley JC; Hudson M; Kanning KC; Schecterson LC; Bothwell M
J Neurochem; 2005 Sep; 94(5):1189-201. PubMed ID: 15992373
[TBL] [Abstract][Full Text] [Related]
15. Chronic treatment with a novel γ-secretase modulator, JNJ-40418677, inhibits amyloid plaque formation in a mouse model of Alzheimer's disease.
Van Broeck B; Chen JM; Tréton G; Desmidt M; Hopf C; Ramsden N; Karran E; Mercken M; Rowley A
Br J Pharmacol; 2011 May; 163(2):375-89. PubMed ID: 21232036
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels.
Rakover I; Arbel M; Solomon B
Neurodegener Dis; 2007; 4(5):392-402. PubMed ID: 17536186
[TBL] [Abstract][Full Text] [Related]
17. Amyloid-β protein (Aβ) Glu11 is the major β-secretase site of β-site amyloid-β precursor protein-cleaving enzyme 1(BACE1), and shifting the cleavage site to Aβ Asp1 contributes to Alzheimer pathogenesis.
Deng Y; Wang Z; Wang R; Zhang X; Zhang S; Wu Y; Staufenbiel M; Cai F; Song W
Eur J Neurosci; 2013 Jun; 37(12):1962-9. PubMed ID: 23773065
[TBL] [Abstract][Full Text] [Related]
18. The novel gamma secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouse.
Best JD; Smith DW; Reilly MA; O'Donnell R; Lewis HD; Ellis S; Wilkie N; Rosahl TW; Laroque PA; Boussiquet-Leroux C; Churcher I; Atack JR; Harrison T; Shearman MS
J Pharmacol Exp Ther; 2007 Feb; 320(2):552-8. PubMed ID: 17099072
[TBL] [Abstract][Full Text] [Related]
19. Modulation of γ-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice.
Rogers K; Felsenstein KM; Hrdlicka L; Tu Z; Albayya F; Lee W; Hopp S; Miller MJ; Spaulding D; Yang Z; Hodgdon H; Nolan S; Wen M; Costa D; Blain JF; Freeman E; De Strooper B; Vulsteke V; Scrocchi L; Zetterberg H; Portelius E; Hutter-Paier B; Havas D; Ahlijanian M; Flood D; Leventhal L; Shapiro G; Patzke H; Chesworth R; Koenig G
Mol Neurodegener; 2012 Dec; 7():61. PubMed ID: 23249765
[TBL] [Abstract][Full Text] [Related]
20. Dynamics of Aβ42 reduction in plasma, CSF and brain of rats treated with the γ-secretase modulator, GSM-10h.
Hawkins J; Harrison DC; Ahmed S; Davis RP; Chapman T; Marshall I; Smith B; Mead TL; Medhurst A; Giblin GM; Hall A; Gonzalez MI; Richardson J; Hussain I
Neurodegener Dis; 2011; 8(6):455-64. PubMed ID: 21389687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
